Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., filed a Form 4 on November 20, 2026, disclosing a purchase of 50,000 shares of common stock on November 19, 2026.

Key Highlights

  • Reporting person: Thomas K. Equels, identified in the filing as CEO and President, and as a Director of AIM ImmunoTech Inc.
  • Transaction: Purchase (transaction code P) of 50,000 shares of common stock on November 19, 2026.
  • Price paid: $0.131 per share, according to the filing.
  • Resulting ownership: Equels directly owned 436,095 shares following the reported transaction.
  • No derivative securities: Table II of the filing contains no reported derivative security transactions.

Equels Purchases Common Stock Directly at $0.131 on November 19, 2026

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 20, 2026, Thomas K. Equels acquired 50,000 shares of AIM ImmunoTech Inc. (NYSE American:AIM) common stock on November 19, 2026, at a price of $0.131 per share. The transaction is recorded under transaction code P, indicating an open-market purchase. The filing reports that Equels holds the shares directly.

Following this transaction, the filing states that Equels beneficially owned 436,095 shares of common stock directly. No deemed execution date was noted for the transaction, and no transactions in derivative securities were reported in Table II of the filing. The filing was submitted by one reporting person and was not indicated as an amendment to a prior filing.

Equels is listed in the filing as both a Director and an Officer with the title of CEO and President. His address is listed in Ocala, Florida. The filing was signed by Thomas K. Equels and dated November 20, 2026.

What Was Disclosed

AIM ImmunoTech Inc.'s CEO and President, Thomas K. Equels, disclosed an open-market purchase of 50,000 shares of common stock at $0.131 per share on November 19, 2026, resulting in direct beneficial ownership of 436,095 shares.